Accent Therapeutics Advances ATX-295 at ASCO
LEXINGTON, Mass., May 21, 2026 Accent Therapeutics has announced the presentation of a Trial in Progress poster for its...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LEXINGTON, Mass., May 21, 2026 Accent Therapeutics has announced the presentation of a Trial in Progress poster for its...
INGELHEIM, Germany & RIDGEFIELD, Conn., May 21, 2026 Boehringer Ingelheim has unveiled significant new oncology data at the 2026...
